艾曲泊帕与静脉注射免疫球蛋白用于免疫性血小板减少症围手术期管理的成本效益比较
基于随机试验的患者水平数据,从加拿大公共卫生保健支付方角度,比较围手术期艾曲泊帕50 mg每日起始剂量与静脉注射免疫球蛋白(IVIG)1或2 g/kg的成本效益。艾曲泊帕组n=38,IVIG组n=36。围手术期使用艾曲泊帕每名患者节省413加元,即使无支付意愿其成本效益概率为70%。基于IVIG剂量的敏感性分析显示,高剂量IVIG(2 g/kg)时艾曲泊帕每名患者节省2714加元,低剂量IVIG(1 g/kg)时艾曲泊帕平均成本高562加元。
要点
- 围手术期艾曲泊帕较IVIG每名患者节省413加元。
- 即使无支付意愿,艾曲泊帕具成本效益的概率为70%。
- 高剂量IVIG(2 g/kg)时艾曲泊帕节省2714加元,低剂量(1 g/kg)时平均成本高562加元。
核心结论
- 基于证明非劣效性的随机试验数据,围手术期使用艾曲泊帕管理ITP比IVIG成本更低。
研究设计与样本
- 基于随机试验患者水平数据的成本效益分析,从加拿大公共卫生保健支付方角度,观察期从术前第21天至术后第28天。
- 艾曲泊帕组n=38,IVIG组n=36;艾曲泊帕50 mg每日起始剂量,IVIG 1或2 g/kg(根据当地实践)。
- 资源利用数据来自试验数据,单位成本来自安大略省福利计划、安大略省药物处方集和二手来源,所有成本调整为2020年加元。
- 计算所有随机患者的每名患者增量成本,使用非参数自举法处理不确定性。
主要发现
- 围手术期使用艾曲泊帕每名患者节省413加元。
- 与IVIG相比,即使无支付意愿,艾曲泊帕具成本效益的概率为70%。
- 基于IVIG剂量的敏感性分析:高剂量IVIG(2 g/kg)时艾曲泊帕每名患者节省2714加元;低剂量IVIG(1 g/kg)时艾曲泊帕平均成本高562加元。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Eltrombopag has been shown to be noninferior to intravenous immunoglobulin (IVIG) for improving perioperative platelet counts in patients with immune thrombocytopenia (ITP) in a randomized trial; thus, cost is an important factor for treatment and policy decisions. We used patient-level data from the trial to conduct a cost-effectiveness analysis comparing perioperative eltrombopag 50 mg daily starting dose, with IVIG 1 or 2 g/kg (according to local practice) from a Canadian public health care payer's perspective over the observation period, from preoperative day 21 to postoperative day 28. Resource utilization data were obtained from the trial data (eltrombopag, n = 38; IVIG, n = 36), and unit costs were collected from the Ontario Schedule of Benefits, Ontario Drug Formulary, and secondary sources. All costs were adjusted to 2020 Canadian dollars. We calculated the incremental cost per patient for all patients randomized. Uncertainty was addressed using nonparametric bootstrapping. The use of perioperative eltrombopag for patients with ITP resulted in a cost-saving of $413 Canadian per patient. Compared with IVIG, the probability of eltrombopag being cost effective was 70% even with no willingness to pay. In a sensitivity analysis based on IVIG dose, we found that with the higher dose of IVIG (2 g/kg), eltrombopag saved $2,714 per patient, whereas with the lower dose of IVIG (1 g/kg), eltrombopag had a higher mean cost of $562 per patient. In summary, based on data from the randomized trial that demonstrated noninferiority, the use of eltrombopag for the management of ITP in the perioperative setting was less costly than IVIG.
引用
- Kaur MN, Arnold DM, Heddle NM, et al. Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. Blood Adv. 2022. PMID: 34781363. doi:10.1182/bloodadvances.2021005627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。